Three-year follow-up of a phase II study of radium-223 dichloride in Japanese patients with symptomatic castration-resistant prostate cancer and bone metastases.

CONCLUSIONS: In Japanese patients with symptomatic mCRPC and bone metastases, radium-223 had a favorable long-term safety profile with no second primary malignancies reported. Taken together with median OS, which was comparable to that in the pivotal phase III ALSYMPCA study, these results support continued benefit from radium-223 in Japanese patients with mCRPC. PMID: 30875000 [PubMed - as supplied by publisher]
Source: Clinical Genitourinary Cancer - Category: Cancer & Oncology Authors: Tags: Int J Clin Oncol Source Type: research

Related Links:

Publication date: Available online 12 July 2020Source: Seminars in Cancer BiologyAuthor(s): Bo Ma, Alan Wells, Liang Wei, Junnian Zheng
Source: Seminars in Cancer Biology - Category: Cancer & Oncology Source Type: research
Publication date: Available online 11 July 2020Source: Reports of Practical Oncology &RadiotherapyAuthor(s): Manasa Veluvolu, Mausam Patel, Ganesh Narayanasamy, Thomas Kim
Source: Reports of Practical Oncology and Radiotherapy - Category: Cancer & Oncology Source Type: research
Publication date: Available online 12 July 2020Source: Journal of Geriatric OncologyAuthor(s): Tea Reljic, Marina Sehovic, Jeffrey Lancet, Jongphil Kim, Najla Al Ali, Benjamin Djulbegovic, Martine Extermann
Source: Journal of Geriatric Oncology - Category: Cancer & Oncology Source Type: research
Publication date: Available online 13 June 2020Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Thejus T. Jayakrishnan, Veli Bakalov, Yazan Samhouri, Rodney E. Wegner, Santhosh Sadashiv
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Publication date: Available online 12 July 2020Source: Acta Pharmaceutica Sinica BAuthor(s): Jianwei Zheng, Junfeng Wang, Qian Wang, Hongye Zou, Hong Wang, Zhenhua Zhang, Jianghe Chen, Qianqian Wang, Panxia Wang, Yueshan Zhao, Jing Lu, Xiaolei Zhang, Songtao Xiang, Haibin Wang, Jinping Lei, Hong-Wu Chen, Peiqing Liu, Yonghong Liu, Fanghai Han, Junjian Wang
Source: Acta Pharmaceutica Sinica B - Category: Cancer & Oncology Source Type: research
Source: Cancer Management and Research - Category: Cancer & Oncology Tags: Cancer Management and Research Source Type: research
Source: OncoTargets and Therapy - Category: Cancer & Oncology Tags: OncoTargets and Therapy Source Type: research
Source: Cancer Management and Research - Category: Cancer & Oncology Tags: Cancer Management and Research Source Type: research
Source: Cancer Management and Research - Category: Cancer & Oncology Tags: Cancer Management and Research Source Type: research
ConclusionsIn Japanese patients with symptomatic mCRPC and bone metastases, radium-223 had a favorable long-term safety profile with no second primary malignancies reported. Taken together with median OS, which was comparable to that in the pivotal phase III ALSYMPCA study, these results support continued benefit from radium-223 in Japanese patients with mCRPC.
Source: International Journal of Clinical Oncology - Category: Cancer & Oncology Source Type: research
More News: Acute Leukemia | Acute Myeloid Leukemia | Anemia | Aplastic Anemia | Bone Cancers | Cancer | Cancer & Oncology | Hematology | Japan Health | Leukemia | Myelodysplastic Syndrome | Prostate Cancer | Study